Latest Regulatory Scrutiny News

ASX Limited reported a solid FY25 financial performance with a 7.5% rise in underlying net profit and a higher fully franked dividend, while advancing its CHESS replacement project amid ongoing regulatory scrutiny.

ASX Limited reported a robust FY25 with revenue and underlying profit growth, while navigating regulatory scrutiny following a major settlement incident. The company advances its technology transformation and sustainability agenda as it seeks to rebuild trust and deliver shareholder value.

Cobre Limited’s CBEO securities have been suspended from ASX quotation due to non-compliance with key listing rules, raising questions about the company’s regulatory standing.

Santos Limited has agreed to extend the exclusivity period with the XRG Consortium, allowing more time to finalize due diligence for a potential A$8.89 per share cash takeover. The extension keeps the door open for competing bids, maintaining shareholder options.

West Coast Silver Limited has responded to an ASX query about recent share price and volume spikes, confirming no undisclosed material information and providing an update on its ongoing exploration assay program.

Sequoia Financial Group reports robust FY25 growth with improved margins and a fully franked dividend, while navigating regulatory scrutiny and governance reforms.

Emu NL has lodged a formal review application against the Takeovers Panel's recent variation of orders, signaling continued regulatory tension in its takeover proceedings.

ASX has revealed it expects to incur an additional $25 million to $35 million in operating expenses in FY26 due to the ongoing ASIC compliance inquiry. Despite this, the company remains committed to its five-year strategy focused on technology and risk management.

Rhythm Biosciences has responded to an ASX price query following a sudden surge in its share price and trading volume, confirming no undisclosed information is driving the activity.

Hudson Investment Group faces intense scrutiny from ASX after its auditor issued a Disclaimer of Opinion on the 2024 financial report, citing doubts over a $2.4 million property receivable and the company’s going concern status.

Alterity Therapeutics faces ASX scrutiny after mistakenly marking multiple announcements as market sensitive, prompting a review of its disclosure practices. The biotech denies any intent to manipulate its share price despite repeated errors.

The Lederer Group has announced an off-market takeover offer for all stapled securities in the Elanor Commercial Property Fund at 70 cents each, representing a premium over recent trading prices. The bid comes amid governance concerns and a proposed overhaul of the fund’s management structure.